Targeted treatment of multiple myeloma with a radioiodinated small molecule radiopharmaceutical

Click to increase image sizeClick to decrease image size

Disclosure statement

M.O., R.M., and F.A. hold a patent on APC analogs for multiple myeloma imaging and therapy. M.O. and N.S.C. have been past consultants for Cellectar Biosciences, Inc., the license holder of CLR 131. The authors have no other conflict of interest to declare.

Author contributions

M.O. was responsible for the overall design, data analysis, data interpretation, and manuscript preparation. A.S. performed experiments, statistically analyzed and plotted data, and edited the manuscript. G.E.W compiled data and wrote the manuscript. S.B. and R.M. performed animal experiments. D.C.B. and T.P. collected samples and performed experiments. N.S.C. and F.A. provided critical advice, clinical samples, cell lines, and edited the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors thank Mohammed Farhoud, Ph.D., and Benjamin Titz, Ph.D., for assistance with animal imaging experiments, Ellen Hebron for expert technical help, and Jens Eickhoff, Ph.D., for help with statistical analysis. The authors also thank James P. Zacny, Ph.D., for his editorial work. The authors thank Cellectar Biosciences Inc., Florham Park, NJ, USA, for providing APC derivatives for our studies.

Additional information

Funding

This work was supported by NIH/NCI [P30CA014520] (UW Carbone Cancer Center Support Grant), the Midwest Athletes Against Childhood Cancer (MACC) Fund (M.O.), Young Investigator Sub-Award from St. Baldrick’s Pediatric Dream Team Translational Research Grant, Stand Up To Cancer [SU2C-AACR-DT1113] (M.O.) and the University of Wisconsin Trillium Fund for Myeloma Research.